Skip Navigation

Matthew Oser, MD, PhD


Make an Appointment

Physician

  • Instructor in Medicine at Dana-Farber Cancer Institute and Harvard Medical School

Clinical Interests

  • Thoracic oncology

Contact Information

  • Office Phone Number617-582-8668

Bio

Dr. Oser received his MD and PhD degrees from Albert Einstein College of Medicine in 2011. He received internal medicine training at Brigham and Women’s Hospital and his medical oncology fellowship training at Dana-Farber/Harvard Cancer Center. He is currently an Instructor in Medicine at Dana-Farber Cancer Institute and Harvard Medical School where he runs a research laboratory focused on small cell lung cancer and is a medical oncologist.

Board Certification:

  • Internal Medicine, 2014
  • Medical Oncology , 2016

Fellowship:

  • Dana-Farber/Harvard Cancer Center

Residency:

  • Brigham and Women's Hospital

Medical School:

  • Albert Einstein College of Medicine

Recent Awards:

  • Damon Runyon Clinical Investigator Award (2019)

Research

Identification of Novel Dependencies in Small Cell Lung Cancer (SCLC) that are a Consequence of Loss of Function Mutations in Tumor Suppressor Genes or from SCLCs Neuroendocrine Differentiation State
Although small cell lung cancer (SCLC) is initially highly responsive to chemotherapy, the disease recurs in nearly all patients in less than a year. At recurrence, there are no approved targeted therapies. Genomic sequencing of human SCLCs has shown that SCLCs have no actionable mutations and that nearly all SCLCs harbor loss of function (LOF) mutations in the tumor suppressor genes RB1 and TP53, while ~25% of SCLCs harbor LOF mutations in NOTCH.  Furthermore, sustained expression of neural/neuroendocrine lineage transcription factors ASCL1 and NEUROD1 are required for SCLC survival. However, ASCL1 and NEUROD1 are transcriptions factors and therefore are not directly druggable.
The Oser laboratory utilizes CRISPR-Cas9 screening approaches to identify new SCLC therapeutic targets that are either required for sustained expression of the neural/neuroendocrine lineage transcription factors ASCL1 and NEUROD1, or that are required for SCLC survival as a consequence of LOF mutations in tumor suppressor genes (i.e. are synthetic lethal interactors with SCLC tumor suppressor genes). In addition, we utilize a novel genetically-engineered mouse model of SCLC developed using CRISPR-Cas9 to study the consequences of inactivating novel candidate therapeutic targets during SCLC tumorigenesis. Ultimately, the Oser laboratory seeks to discover new targeted therapies for SCLC patients that function as synthetic lethal interactors with SCLC tumor suppressor genes or that function to block neuroendocrine differentiation.

Schade AE, Oser MG, Nicholson HE, DeCaprio JA. Cyclin D-CDK4 relieves cooperative repression of proliferation and cell cycle gene expression by DREAM and RB. Oncogene. 2019 Jun; 38(25):4962-4976.
View in: PubMed

Harris IS, Endress JE, Coloff JL, Selfors LM, McBrayer SK, Rosenbluth JM, Takahashi N, Dhakal S, Koduri V, Oser MG, Schauer NJ, Doherty LM, Hong AL, Kang YP, Younger ST, Doench JG, Hahn WC, Buhrlage SJ, DeNicola GM, Kaelin WG, Brugge JS. Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion. Cell Metab. 2019 May 07; 29(5):1166-1181.e6.
View in: PubMed

Oser MG, Fonseca R, Chakraborty AA, Brough R, Spektor A, Jennings RB, Flaifel A, Novak JS, Gulati A, Buss E, Younger ST, McBrayer SK, Cowley GS, Bonal DM, Nguyen QD, Brulle-Soumare L, Taylor P, Cairo S, Ryan CJ, Pease EJ, Maratea K, Travers J, Root DE, Signoretti S, Pellman D, Ashton S, Lord CJ, Barry ST, Kaelin WG. Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival. Cancer Discov. 2019 02; 9(2):230-247.
View in: PubMed

McBrayer SK, Olenchock BA, DiNatale GJ, Shi DD, Khanal J, Jennings RB, Novak JS, Oser MG, Robbins AK, Modiste R, Bonal D, Moslehi J, Bronson RT, Neuberg D, Nguyen QD, Signoretti S, Losman JA, Kaelin WG. Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase. Proc Natl Acad Sci U S A. 2018 04 17; 115(16):E3741-E3748.
View in: PubMed

Oser MG, Jänne PA. Small-Cell Neuroendocrine Tumors: Cell State Trumps the Oncogenic Driver. Clin Cancer Res. 2018 04 15; 24(8):1775-1776.
View in: PubMed

Zhang C, Li X, Adelmant G, Dobbins J, Geisen C, Oser MG, Wucherpfenning KW, Marto JA, Kaelin WG. Peptidic degron in EID1 is recognized by an SCF E3 ligase complex containing the orphan F-box protein FBXO21. Proc Natl Acad Sci U S A. 2015 Dec 15; 112(50):15372-7.
View in: PubMed

Engelman JA, Oser MG, Niederst MJ, Sequist LV. Transformation from NSCLC to SCLC: when did it happen? - Authors' reply. Lancet Oncol. 2015 Jul; 16(7):e309-10.
View in: PubMed

Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015 Apr; 16(4):e165-72.
View in: PubMed

Oser MG, Jänne PA. A severe photosensitivity dermatitis caused by crizotinib. J Thorac Oncol. 2014 Jul; 9(7):e51-3.
View in: PubMed

Magalhaes MA, Larson DR, Mader CC, Bravo-Cordero JJ, Gil-Henn H, Oser M, Chen X, Koleske AJ, Condeelis J. Cortactin phosphorylation regulates cell invasion through a pH-dependent pathway. J Cell Biol. 2011 Nov 28; 195(5):903-20.
View in: PubMed

Bravo-Cordero JJ, Oser M, Chen X, Eddy R, Hodgson L, Condeelis J. A novel spatiotemporal RhoC activation pathway locally regulates cofilin activity at invadopodia. Curr Biol. 2011 Apr 26; 21(8):635-44.
View in: PubMed

Mader CC, Oser M, Magalhaes MA, Bravo-Cordero JJ, Condeelis J, Koleske AJ, Gil-Henn H. An EGFR-Src-Arg-cortactin pathway mediates functional maturation of invadopodia and breast cancer cell invasion. Cancer Res. 2011 Mar 01; 71(5):1730-41.
View in: PubMed

Oser M, Mader CC, Gil-Henn H, Magalhaes M, Bravo-Cordero JJ, Koleske AJ, Condeelis J. Specific tyrosine phosphorylation sites on cortactin regulate Nck1-dependent actin polymerization in invadopodia. J Cell Sci. 2010 Nov 01; 123(Pt 21):3662-73.
View in: PubMed

Oser M, Dovas A, Cox D, Condeelis J. Nck1 and Grb2 localization patterns can distinguish invadopodia from podosomes. Eur J Cell Biol. 2011 Feb-Mar; 90(2-3):181-8.
View in: PubMed

Oser M, Condeelis J. The cofilin activity cycle in lamellipodia and invadopodia. J Cell Biochem. 2009 Dec 15; 108(6):1252-62.
View in: PubMed

Oser M, Yamaguchi H, Mader CC, Bravo-Cordero JJ, Arias M, Chen X, Desmarais V, van Rheenen J, Koleske AJ, Condeelis J. Cortactin regulates cofilin and N-WASp activities to control the stages of invadopodium assembly and maturation. J Cell Biol. 2009 Aug 24; 186(4):571-87.
View in: PubMed

Desmarais V, Yamaguchi H, Oser M, Soon L, Mouneimne G, Sarmiento C, Eddy R, Condeelis J. N-WASP and cortactin are involved in invadopodium-dependent chemotaxis to EGF in breast tumor cells. Cell Motil Cytoskeleton. 2009 Jun; 66(6):303-16.
View in: PubMed

Philippar U, Roussos ET, Oser M, Yamaguchi H, Kim HD, Giampieri S, Wang Y, Goswami S, Wyckoff JB, Lauffenburger DA, Sahai E, Condeelis JS, Gertler FB. A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis. Dev Cell. 2008 Dec; 15(6):813-28.
View in: PubMed

Su IH, Dobenecker MW, Dickinson E, Oser M, Basavaraj A, Marqueron R, Viale A, Reinberg D, Wülfing C, Tarakhovsky A. Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell. 2005 May 06; 121(3):425-36.
View in: PubMed

Location

Dana-Farber Cancer Institute, Longwood Center (LC4202)
360 Longwood Ave
Boston, MA 02215
Get Directions

Top